靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

doi:10.19438/j.cjoms.2023.03.003

中国口腔颌面外科杂志 ›› 2023, Vol. 21 ›› Issue (3): 225-230.doi: 10.19438/j.cjoms.2023.03.003

靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

汪子恒, 周韧, 严佳, 张磊, 杨雅琼^*, 姜虹^*

上海交通大学医学院附属第九人民医院麻醉科,上海 200011

收稿日期:2023-02-05 修回日期:2023-03-01 出版日期:2023-05-20 发布日期:2023-08-16
通讯作者: 姜虹,E-mail: dr_jianghong@163.com;杨雅琼,E-mail: yangyaqiong228@163.com。^*共同通信作者
作者简介:汪子恒（1997-）,男,在读硕士研究生,E-mail:wzhxzmu@163.com
基金资助:
国家自然科学基金（81801094）

Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain

WANG Zi-heng, ZHOU Ren, YAN Jia, ZHANG Lei, YANG Ya-qiong, JIANG Hong

Department of Anesthesiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2023-02-05 Revised:2023-03-01 Online:2023-05-20 Published:2023-08-16

摘要/Abstract

摘要： 目的：比较靶向表皮生长因子受体（epidermal growth factor receptor,EGFR）治疗联合化疗与单纯化疗对口腔癌痛的影响。方法：选择患有慢性癌痛的口腔癌患者90例,根据接受治疗的方式分为单纯化疗组（G0组）和靶向EGFR治疗联合化疗组（G1组）。在患者入院（T0）、治疗后第1天（T1）、第7天（T2）和第3个月末（T3）,使用视觉模拟评分（VAS）和数字疼痛评分表（NRS）评估疼痛强度。在T0和T3,使用自评利兹神经病理性疼痛症状与体征评价量表（S-LANSS）评价患者神经病理性疼痛,记录辅助镇痛药物的使用和睡眠时长;在T3时记录治疗副作用和满意度。采用SPSS 26.0软件包对数据进行统计学分析。结果：G0组和G1组分别纳入31例和59例患者。受试者平均年龄60.64岁,70%为男性。2组患者T0时的VAS和NRS无显著差异,而G1组在T1、T2和T3时的VAS和NRS较G0组显著降低（P<0.05）。G1组较G0组在T3时使用的镇痛药物显著减少（P<0.05）,睡眠时间显著延长（P<0.05）,满意度更高（P<0.05）。结论：靶向EGFR治疗联合化疗相比单纯化疗对口腔癌痛的缓解作用更明显,可减少辅助镇痛药物的使用。

关键词: 口腔癌, 表皮生长因子受体, 化疗, 癌痛

Abstract: PURPOSE: To compare the effect of epidermal growth factor receptor-targeted (EGFR-targeted) therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain. METHODS: Ninety oral cancer patients with chronic cancer pain were divided into chemotherapy alone group (group G0) and EGFR-targeted therapy combined with chemotherapy group (group G1) according to the type of treatment they received. Pain intensity was assessed at baseline (T0), day 1 (T1), day 7 (T2) and at the end of month 3 (T3) using visual analogue scale (VAS) and numerical rating scale for pain(NRS). The patients were assessed for neuropathic pain using self-administrative Leeds neuropathic pain signs and symptoms scale (S-LANSS), and adjunctive analgesic use, sleep duration were recorded at T0 and T3. Treatment side effects and satisfaction were recorded at T3. SPSS 26.0 software package was used to analyze the data. RESULTS: Of the 90 patients, 31 cases were included in G0 group and 59 cases were included in G1 group. The average age of patients was 60.64 years and 70% were male. There was no significant difference in VAS and NRS at T0 between G0 group and G1 group(P>0.05). VAS and NRS at T1, T2 and T3 were significantly lower in G1 group compared to G0 group(P<0.05). Patients in G1 group used significantly less analgesic medication (P<0.05), slept longer(P<0.05) and were more satisfied (P<0.05) than those in G0 group at T3. CONCLUSIONS: EGFR-targeted therapy in combination with chemotherapy are more effective than chemotherapy alone in the alleviation of oral cancer pain and reduce the use of adjuvant analgesics.

Key words: Oral cancer, EGFR, Chemotherapy, Cancer pain

中图分类号:

R739.8

汪子恒, 周韧, 严佳, 张磊, 杨雅琼, 姜虹. 靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响[J]. 中国口腔颌面外科杂志, 2023, 21(3): 225-230.

WANG Zi-heng, ZHOU Ren, YAN Jia, ZHANG Lei, YANG Ya-qiong, JIANG Hong. Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain[J]. China J Oral Maxillofac Surg, 2023, 21(3): 225-230.

参考文献

[1] Bossi P, Giusti R, Tarsitano A, et al.The point of pain in head and neck cancer[J]. Crit Rev Oncol Hematol, 2019, 138: 51-59.
[2] Epstein J B, Elad S, Eliav E, et al.Orofacial pain in cancer: part Ⅱ-clinical perspectives and management[J]. J Dent Res, 2007, 86(6): 506-518.
[3] Celis-Rodríguez E, Díaz Cortés JC, Cárdenas Bolívar YR, et al.Evidence-based clinical practice guidelines for the management of sedoanalgesia and delirium in critically ill adult patients[J]. Med Intensiva (Engl Ed), 2020, 44(3): 171-184.
[4] van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years[J]. Ann Oncol, 2007, 18(9): 1437-1449.
[5] Ayati A, Emami S, Moghimi S, et al.Thiazole in the targeted anticancer drug discovery[J]. Future Med Chem, 2019, 11(15): 1929-1952.
[6] Sharma SV, Bell DW, Settleman J, et al.Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer, 2007, 7(3): 169-181.
[7] Rosell R, Moran T, Queralt C, et al.Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): 958-967.
[8] Magee D, Bachtold S, Brown M, et al.Cancer pain: where are we now?[J]. Pain Manag, 2019, 9(1): 63-79.
[9] Kersten C, Cameron MG.Cetuximab alleviates neuropathic pain despite tumour progression[J]. BMJ Case Rep, 2012: bcr122011 5374.
[10] Kersten C, Cameron MG, Laird B, et al.Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain[J]. Br J Anaesth, 2015, 115(5): 761-767.
[11] Chong IC, Hardingham JE, Townsend AR, et al.Rechallenge with anti-EGFR therapy in metastatic colorectal cancer (mCRC): results from South Australia mCRC registry[J]. Target Oncol, 2020, 15(6): 751-757.
[12] Martin LJ, Smith SB, Khoutorsky A, et al.Epiregulin and EGFR interactions are involved in pain processing[J]. J Clin Invest, 2017, 127(9): 3353-3366.
[13] Puig S, Donica CL, Gutstein HB. EGFR signaling causes morphine tolerance and mechanical sensitization in rats[J]. eNeuro, 2020, 7(2): eneuro.0460-18.2020.
[14] Yang Y, Sun Y, Hu R, et al.Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway[J]. PLoS One, 2021, 16(9): e0256870.
[15] Yang Y, Chen Z, Hu R, et al.Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance[J]. Neuropharmacology, 2021, 196: 108703.
[16] 孙丽立,白玉贤. 头颈鳞癌的靶向治疗进展[J]. 中华临床医师杂志(电子版), 2013, 7(22): 10271-10274.
Sun LL, Bai YX.Advances in targeted therapy for head and neck squamous cell carcinoma[J]. Chinese Journal of Clinician (electronic edition), 2013, 7(22): 10271-10274.
[17] 魏东亮,李智,鞠侯雨, 等. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
Wei DL, Li Z, Ju HY, et al.Mechanism of EGFR-targeted drugs for pain relief in oral cancer[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 219-224.
[18] Maughan TS, Adams RA, Smith CG, et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377(9783): 2103-2114.
[19] Melosky B, Leighl NB, Rothenstein J, et al.Management of egfr tki-induced dermatologic adverse events[J]. Curr Oncol, 2015, 22(2): 123-132.
[20] Kersten C, Cameron MG, Bailey AG, et al.Relief of neuropathic pain through epidermal growth factor receptor inhibition: a randomized proof-of-concept trial[J]. Pain Med, 2019, 20(12): 2495-2505.

靶向EGFR治疗联合化疗与单纯化疗对口腔癌痛的影响

Effect of EGFR-targeted therapy in combination with chemotherapy versus chemotherapy alone on oral cancer pain

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵安玉琢, 石兴莲, 刘欢, 姜健红, 李哲臻, 刘梅. 人工智能在口腔癌早期诊断中的应用研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(5): 493-498.
[2]	高鹏飞, 林洁. 区域神经阻滞技术用于口腔癌缺损皮瓣修复手术的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(4): 400-403.
[3]	郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.
[4]	洪磊, 陈伟良. 口腔癌老年患者术后静脉血栓栓塞症的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(3): 233-238.
[5]	王帅, 何杏芳, 王蕴洁, 吴伟勤, 黄秋雨. 非药物干预对口腔癌患者术后谵妄预防效果的系统评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 279-286.
[6]	周新凯¹,张月影¹,滕晓菊²,邹卫珍²,吴瑞芳². 口腔癌患者二元应对现状及影响因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 170-174.
[7]	陈瑞斌, 陈岚枫. 2011—2017年福建省口腔癌发病及死亡趋势分析[J]. 中国口腔颌面外科杂志, 2024, 22(1): 68-72.
[8]	陈歆旖, 李晨蕾, 秦兴军, 张金凤. 口腔癌患者营养状况变化轨迹及其影响因素分析[J]. 中国口腔颌面外科杂志, 2023, 21(6): 538-547.
[9]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[10]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[11]	周新凯, 滕晓菊, 张月影. 基于CiteSpace口腔癌患者生存质量研究的可视化分析[J]. 中国口腔颌面外科杂志, 2023, 21(6): 586-592.
[12]	翟培淞, 童桐, 刘纯, 马海龙, 张建军. 线粒体拓扑异构酶Ⅰ在头颈鳞癌中的表达及意义[J]. 中国口腔颌面外科杂志, 2023, 21(5): 439-445.
[13]	汤丰榕, 王鹏, 张艳. 饮食护理及心理干预在鼻咽癌放化疗后致口腔黏膜破溃患者中的应用[J]. 中国口腔颌面外科杂志, 2023, 21(5): 491-496.
[14]	陈玉, 陶明, 雷银富, 吴和梅, 彭晓峰, 苟登群. 口腔癌患者术后肺部感染危险因素的meta分析[J]. 中国口腔颌面外科杂志, 2023, 21(5): 511-517.
[15]	李贵忠, 李洁莹, 周凯, 孟宇翔, 王可心, 葛胜优, 宋凯, 冯元勇, 陶月琴, 展晓红, 尚伟. 淋巴结外扩展对口腔鳞癌患者TNM分期及生存预后的影响[J]. 中国口腔颌面外科杂志, 2023, 21(4): 377-383.